Brooks Lab.

Which are the latest news on Brooks Lab.?

Why is Brooks Laboratories Ltd falling/rising?

As of 03-Aug, Brooks Laboratories Ltd's stock price has risen to Rs 62.95, reflecting a 3.2% increase after a two-day gain of 7.42%. Despite longer-term declines, recent performance indicates a short-term recovery, supported by increased investor interest and sector outperformance.

As of 03-Aug, Brooks Laboratories Ltd is experiencing a rise in its stock price, currently at Rs 62.95, reflecting an increase of Rs 1.95 or 3.2%. This upward movement follows a two-day consecutive gain, during which the stock has returned 7.42%. Despite opening lower today with a loss of 3.28%, the stock managed to reach an intraday high of Rs 63.65, indicating some recovery during the trading session.<BR><BR>Additionally, the stock has outperformed its sector by 2.77% today, suggesting that it is gaining traction compared to its peers. There has also been a notable increase in investor participation, with delivery volume rising by 6.39% against the five-day average, which may indicate growing interest among investors. <BR><BR>While the stock has shown significant declines over longer periods, such as a 21.56% drop year-to-date and a 60.16% decline over the past year, the recent performance suggests a short-term recovery phase. The current price is above the 5-day and 100-day moving averages, although it remains below the 20-day, 50-day, and 200-day moving averages, indicating mixed signals regarding its longer-term trend. Overall, the combination of recent gains, improved investor participation, and sector outperformance contributes to the current rise in Brooks Laboratories Ltd's stock price.

Should I buy, sell or hold Brooks Laboratories Ltd?

How big is Brooks Lab.?

As of 10th June, Brooks Laboratories Ltd has a market capitalization of 208.00 Cr, with recent net sales of 85.74 Cr and a net profit of 24.58 Cr. Shareholder's funds are 98.10 Cr, and total assets are valued at 123.69 Cr.

As of 10th June, Brooks Laboratories Ltd has a market capitalization of 208.00 Cr, categorizing it as a Micro Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 85.74 Cr and a Net Profit of 24.58 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 98.10 Cr and Total Assets valued at 123.69 Cr.

Who are in the management team of Brooks Lab.?

The management team of Brooks Lab consists of Rajnish Kumar Bedi, Deepak Mahajan, and Sonia Gupta as Independent Directors, and Kaushalya Singh and Jitendra Pratap Singh as Whole Time Directors.

The management team of Brooks Lab includes the following members:<BR><BR>1. **Rajnish Kumar Bedi** - Independent Director<BR>2. **Deepak Mahajan** - Independent Director<BR>3. **Sonia Gupta** - Independent Director<BR>4. **Kaushalya Singh** - Whole Time Director<BR>5. **Jitendra Pratap Singh** - Whole Time Director<BR><BR>If you need more details about their roles or responsibilities, feel free to ask!

Who are the peers of the Brooks Lab.?

Peers of Brooks Lab. include BDH Industries, Kerala Ayurveda, Nectar Lifesci., Aarey Drugs, Syschem (India), Oxygenta Pharma, Coral Labs., and Sanjiv.Parant. Brooks Lab. has Below Average management risk and growth ratings, with a 1-year return of -48.98%, better than Kerala Ayurveda but worse than BDH Industries at 49.43%.

Peers: The peers of Brooks Lab. are BDH Industries, Kerala Ayurveda, Nectar Lifesci., Aarey Drugs, Syschem (India), Oxygenta Pharma, Coral Labs., and Sanjiv.Parant.<BR><BR>Quality Snapshot: Excellent management risk is observed at BDH Industries and Sanjiv.Parant., while Average management risk is found at Nectar Lifesci., and the rest. Below Average management risk is noted at Kerala Ayurveda, Aarey Drugs, Syschem (India), Brooks Lab., Coral Labs., and the rest. Growth ratings show Good growth at Syschem (India) and the rest have Below Average growth, including Brooks Lab., Kerala Ayurveda, Nectar Lifesci., Aarey Drugs, and Coral Labs. Capital Structure is Excellent at BDH Industries and Coral Labs., while Good capital structure is seen at Syschem (India) and the rest have Below Average capital structure, including Brooks Lab.<BR><BR>Return Snapshot: The peer with the highest 1-year return is BDH Industries at 49.43%, while the lowest is Kerala Ayurveda at -64.05%. Brooks Lab.'s 1-year return is -48.98%, which is higher than Kerala Ayurveda's but lower than BDH Industries'. Additionally, Syschem (India), Brooks Lab., Oxygenta Pharma, and Kerala Ayurveda have negative six-month returns.

What does Brooks Lab. do?

Brooks Laboratories Ltd is a micro-cap pharmaceutical manufacturing company focused on producing injectables, tablets, and dry syrups for domestic markets. As of March 2026, it reported net sales of 20 Cr and a net profit of 2 Cr, with a market cap of INR 208 Cr.

Overview: <BR>Brooks Laboratories Ltd is a pharmaceutical manufacturing company operating in the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap.<BR><BR>History: <BR>The company was incorporated on January 23, 2002, and has been focused on manufacturing injectables, tablets, and dry syrups for domestic customers. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 20 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 2 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 208 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 8.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.01 <BR>Return on Equity: 20.04% <BR>Price to Book: 1.64 <BR><BR>Contact Details: <BR>Address: Village Kishanpura, Nilagarh Road Baddi Solan Himachal Pradesh : 174101 <BR>Tel: 91-1795-654001/02/03 <BR>Email: investors@brookslabs.net <BR>Website: http://www.brookslabs.net

Are Brooks Laboratories Ltd latest results good or bad?

Brooks Laboratories Ltd's latest results are concerning, showing a 31.08% decline in net profit and a 29.34% drop in net sales, marking their weakest performance in eight quarters. The significant decline in operating margin and misleading profit after tax margin indicate serious operational challenges that investors should monitor closely.

The latest results for Brooks Laboratories Ltd are concerning and indicate significant operational challenges. In the quarter ending December 2025, the company reported a consolidated net profit of ₹5.50 crore, which represents a decline of 31.08% compared to the previous quarter. Additionally, net sales dropped sharply by 29.34% quarter-on-quarter to ₹16.57 crore, marking the weakest performance in eight quarters. <BR><BR>The operating margin also suffered, falling to 4.41%, the lowest level recorded in recent history, down from 10.75% in the previous quarter. This decline in profitability raises red flags about the company's operational efficiency and ability to sustain its business model.<BR><BR>Furthermore, the reported profit after tax margin of 33.19% is misleading as it was significantly influenced by tax adjustments rather than genuine operational performance. The underlying operational deterioration suggests that the company is facing serious challenges in maintaining its revenue and profitability.<BR><BR>Overall, the results can be characterized as bad, reflecting a troubling trend that investors should closely monitor.

When is the next results date for Brooks Laboratories Ltd?

The next results date for Brooks Laboratories Ltd is 06 February 2026.

The next results date for Brooks Laboratories Ltd is scheduled for 06 February 2026.

How has been the historical performance of Brooks Lab.?

Brooks Lab's historical performance shows a recovery in net sales from 63.20 Cr in Mar'23 to 82.56 Cr in Mar'25, alongside improved operating profit of 4.94 Cr, despite a consolidated net loss of -9.97 Cr in Mar'25. Total assets increased to 123.69 Cr, and cash flow from operations turned positive at 2.00 Cr, indicating a potential turnaround.

Answer:<BR>The historical performance of Brooks Lab shows a fluctuating trend in key financial metrics over the past five years.<BR><BR>Breakdown:<BR>Brooks Lab's net sales increased from 63.20 Cr in Mar'23 to 82.56 Cr in Mar'25, indicating a recovery from a dip in Mar'22 when sales were at 91.08 Cr. Total operating income followed a similar trend, rising to 82.56 Cr in Mar'25 from a low of 63.20 Cr in Mar'23. However, total expenditure decreased from 105.44 Cr in Mar'22 to 77.62 Cr in Mar'25, contributing to an operating profit of 4.94 Cr in Mar'25, a significant improvement from a loss of 26.42 Cr in Mar'23. Despite this, the company reported a consolidated net profit of -9.97 Cr in Mar'25, although this was an improvement from -19.59 Cr in Mar'24. The earnings per share also showed a trend of improvement, moving from -8.46 in Mar'23 to -3.38 in Mar'25. On the balance sheet, total assets increased to 123.69 Cr in Mar'25 from 90.45 Cr in Mar'24, while total liabilities also rose to 123.69 Cr in Mar'25, reflecting a stable financial position. Cash flow from operating activities turned positive at 2.00 Cr in Mar'25, contrasting with negative cash flows in previous years, indicating a potential turnaround in operational efficiency.

Is Brooks Lab. overvalued or undervalued?

As of October 20, 2025, Brooks Lab. is considered overvalued with a high PE ratio of 173.77 and an EV to EBITDA of 46.27, alongside poor financial performance and a year-to-date stock decline of 35.25%, making it an unfavorable investment at its current price of 119.75.

As of 20 October 2025, the valuation grade for Brooks Lab. has moved from very expensive to expensive, indicating a slight improvement in its perceived value. However, the company remains overvalued based on key financial metrics. The PE ratio stands at an exceptionally high 173.77, while the EV to EBITDA ratio is 46.27, both of which are significantly higher than its peers. In contrast, Sun Pharma has a PE ratio of 35.32 and an EV to EBITDA of 23.96, while Cipla, considered attractive, has a PE of 24.56 and an EV to EBITDA of 17.35.<BR><BR>Overall, Brooks Lab. appears to be overvalued given its high valuation ratios and poor financial performance, including a negative ROE of -10.15% and a low ROCE of 3.18%. Recent stock performance has also been disappointing, with a year-to-date decline of 35.25%, compared to a 7.97% increase in the Sensex, further reinforcing the notion that the stock is not a favorable investment at its current price of 119.75.

Who are the top shareholders of the Brooks Lab.?

The top shareholders of Brooks Lab include Atul Ranchal with 19.24%, Quant Mutual Fund at 9.9%, and individual investors collectively holding 31.86%. Foreign institutional investors hold a minimal 0.05%.

The top shareholders of Brooks Lab include the promoters, with Atul Ranchal holding the highest individual stake at 19.24%. Additionally, Quant Mutual Fund, specifically through the Quant Business Cycle Fund, is the highest public shareholder with a holding of 9.9%. The company also has mutual funds holding 9.9% through one scheme and foreign institutional investors (FIIs) holding a minimal 0.05%. Individual investors collectively own 31.86% of the company.

Has Brooks Lab. declared dividend?

No Dividend History Available